XmAb 2+1 PSMA x CD3

XmAb 2+1 PSMA x CD3 is an investigational **bispecific monoclonal antibody** from **Xencor** designed as a **T-cell engager** for **prostate cancer**. It uses Xencor's XmAb 2+1 format, incorporating an engineered heterodimeric Fc domain with **two PSMA-binding arms** and **one CD3-binding arm** to redirect T cells toward **prostate-specific membrane antigen-expressing tumor cells**. The molecule was described as having affinity-tuned binding to both PSMA and CD3 to improve selectivity for high-PSMA tumor cells while reducing activity on normal tissues with lower PSMA expression. Based on the provided information, this specific PSMA x CD3 construct appears to be a **preclinical research candidate** rather than a clinically named development asset.

Other names

PSMA x CD3 XmAb 2+1 bispecific antibodyXmAb 2+1 PSMA-CD3